Streetbeat News

UNCY

Unicycive Therapeutics, Inc.

https://www.unicycive.com

Industry

Biotechnology

Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.

Open

0.58

Mkt cap

56M

Volume

2.2M

High

0.61

P/E Ratio

-1.64

52-wk high

1.82

Low

0.55

Div yield

N/A

52-wk low

0.20

Unicycive Therapeutics shares are trading higher after the United States Patent and Trademark Office granted the company a patent on UNI-494 to treat acute kidney injury.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 11:06 am

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) has secured a U.S. patent for its kidney disease treatment UNI-494, valid until 2040. The patent covers the method of treating acute kidney injury and contrast-induced nephropathy using the UNI-494 compound.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 11:05 am

Key stocks to watch on Monday include Greenbrier Companies, Nature Wood Group, Fortress Biotech, Sonic Automotive, and Unicycive Therapeutics. Greenbrier is expected to report earnings, Nature Wood Group announced a CEO change, Fortress Biotech paused dividend payments, Sonic Automotive disclosed a cybersecurity incident, and Unicycive Therapeutics filed for the resale of shares.

Portfolio Pulse from Avi Kapoor

July 08, 2024 | 7:10 am

Unicycive Therapeutics Inc has filed with the SEC for the resale of up to 50 million shares by the selling stockholders.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2024 | 8:03 pm

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) has been included in the Russell Microcap Index following the 2024 Russell US Indexes annual reconstitution, effective July 1, 2024.

Portfolio Pulse from Benzinga Newsdesk

July 01, 2024 | 11:10 am

Unicycive Therapeutics shares are trading lower following the announcement of results from the Oxylanthanum Carbonate UNI-OLC-201 pivotal clinical trial.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 6:50 pm

HC Wainwright & Co. has reiterated its Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a price target of $4.5.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 4:12 pm

Unicycive Therapeutics announced favorable results from the Oxylanthanum Carbonate UNI-OLC-201 pivotal trial, highlighting its tolerability and safety. The company plans to submit a New Drug Application in Q3 2024.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 11:32 am

12 health care stocks experienced significant movements in Tuesday's after-market session. Notable gainers include Autonomix Medical (AMIX), Unicycive Therapeutics (UNCY), and Venus Concept (VERO). Significant losers include Calidi Biotherapeutics (CLDI), BioSig Technologies (BSGM), and ThermoGenesis Holdings (THMO).

Portfolio Pulse from Benzinga Insights

June 11, 2024 | 8:31 pm

Benchmark analyst Bruce Jackson has reiterated a Speculative Buy rating on Unicycive Therapeutics (NASDAQ:UNCY) and maintained a $3 price target.

Portfolio Pulse from Benzinga Newsdesk

June 03, 2024 | 3:59 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.